Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapyJoel D. Leverson, Andrew J. Souers, Dolores Diaz et al.|Science Translational Medicine|2015Cited by 541
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug ConjugateAndrew C. Phillips, Edward B. Reilly, Erwin R. Boghaert et al.|Molecular Cancer Therapeutics|2018Cited by 52